Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 500-046-6 | CAS number: 26183-52-8 1 - 2.5 moles ethoxylated
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 982
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- 68951-67-7
- EC Number:
- 614-831-7
- Cas Number:
- 68951-67-7
- IUPAC Name:
- 68951-67-7
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Shell Toxicology Laboratory
- Age at study initiation: 5 weeks
- Mean body weight at study initiation: 138 - 143 g (males), 130 - 132 g (females)
- Housing: animals were individually housed in suspended polypropylene cages which had stainless steel grid floors and cellulose-lined trays underneath (North Kent Plastic Cages Ltd., Dartford, Kent, UK)
- Diet: expanded powdered diet (Spratts Laboratory diet No. 2, LAD 2, Spratts Patent Ltd., Barking, Essex, UK), formulated with the appropriate amount of test material, ad libitum
- Water: ad libitum
- Acclimation period: 14 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C):18.3 - 24.4
- Humidity (%): 45 - 70
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- DIET PREPARATION
- Mixing appropriate amounts with LAD 2: Diet containing 10000 ppm of the test material was prepared by mixing the melted material with acetone in the ratio of 2:1 w/v to make a uniform mix with LAD 2 powdered diet. The 3000 ppm and 1000 ppm concentrations were prepared by mixing the 10000 ppm diet with the appropriate amount of untreated diet and the 300 ppm concentration was prepared by mixing the 3000 ppm diet with the appropriate amount of untreated diet. The plain diet for the control group was prepared with acetone.
- Storage temperature of food: ambient temperature
- Rate of preparation of diet (frequency): The diets were prepared in three batches. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The analytical method used is based upon the method of Tobin et. al. (1976) The test material is extracted, degraded and derivatised with hydrogen bromide in acetic acid into 1,2-dibromoethane, 1-bromotetradecane and 1-bromopentadecane. These derivatives are analysed and quantified by gas-liquid chromatography as a measure of the test material content.
The recovery based on the derivate 1,2-dibromoethane was 103, 114 and 146% at 10000, 3000 and 1000 ppm; 106, 97 and 128% at 10000, 3000 and 1000 ppm and 104% at 10.000 ppm for the first, second and third batch of diet, respectively.
The recovery based on the derivate 1-bromotetradecane was 103, 102 and 90% at 10000, 3000 and 1000 ppm; 96, 75 and 106% at 10000, 3000 and 1000 ppm and 105 and 102% at 10.000 ppm for the first, second and third batch of diet, respectively. Due to interference with dietary peaks the recovery was repeated using a modified protocol. The recovery based on the derivate 1-bromotetradecane was 114, 102, 104 and 90% at 10000, 3000, 1000 and 300 ppm; 75, 84 and 96% at 3000, 1000 and 300 ppm for the first and second batch of diet, respectively.
The recovery based on the derivate 1-bromopentadecane was 108, 111 and 79% at 10000, 3000 and 1000 ppm; 91, 69 and 105% at 10000, 3000 and 1000 ppm and 134 and 87% at 10.000 and 300 ppm for the first, second and third batch of diet, respectively.
Re-analysis of the 300 ppm diet of batch 3 proved the stability of the test material in the diet (102 vs 93% based on the derivate 1-bromotetradecane and 87 vs. 93% based on the derivate 1-bromopentadecane.
Although not all results were within the protocol specification of ± 10% the analytical verification proved the nominal dose level.
Reference: Tobin et al. 1976, Water Research, 10 (6), 529-535 - Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- daily, 7 days/week
Doses / concentrationsopen allclose all
- Dose / conc.:
- 300 ppm
- Remarks:
- nominal in diet
- Dose / conc.:
- 1 000 ppm
- Remarks:
- nominal in diet
- Dose / conc.:
- 3 000 ppm
- Remarks:
- nominal in diet
- Dose / conc.:
- 10 000 ppm
- Remarks:
- nominal in diet
- Dose / conc.:
- 15 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 50 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 150 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 500 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 24 (control), 12 (dose groups)
- Control animals:
- other: plain diet mixed with acetone
- Positive control:
- Not applicable
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
Time schedule: All animals were daily examined for overt signs of toxicity, ill-health, mortality or behavioural change.
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: Yes
Time schedule for examinations: Individual body weights were recorded on Day 0 (prior to dosing) and at weekly intervals thereafter. Body weights were also recorded at terminal kill.
FOOD CONSUMPTION: YES
- Food consumption was recorded at weekly intervals.
WATER CONSUMPTION: No Data
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Haematological investigations were performed on all animals from each test and control group at the end of the study (13 weeks). Terminal blood samples were taken by cardiac puncture. Moreover, blood for the estimation of glucose concentration was obtained from the tail vain of all rats during the eleventh week.
- Animals fasted: No
- How many animals: all animals
- Parameters examined: haemoglobin (Hb), haematocrit (Hct), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC), erythrocyte count (RB), total leukocyte count (WBC) mean cell volume (MCV), prothrombin time (PT), kaolin cephalin clotting time (KCCT), differential leucocyte count, reticulocyte count
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: During the eleventh week blood for the estimation of glucose concentration was obtained from the tail vain of all rats. Clinical chemistry investigations were performed on all animals from each test and control group at the end of the study (13 weeks). Terminal blood samples were taken by cardiac puncture.
- Animals fasted: No
- How many animals: all animals
- Parameters examined: urea nitrogen, total protein, alkaline phosphatase, chloride (Cl-), bilirubin, calcium, sodium (Na+), potassium (K+), cholesterol, glucose, alanine amino transferase (ALT), aspartate amino transferase (AST)
URINALYSIS: Yes
- Time schedule for collection of urine: Urine was collected from 10 male and 10 female rats from each of the control and 10000 ppm dose groups during the eleventh week.
- Metabolism cages used for collection of urine: No data
- Animals fasted: No
- Parameters examined: volume, pH, nitrite, protein, glucose, ketone, urobilinogen, bilirubin, blood, epithelial cells, tubule cells, leucocytes, erythrocytes, sperm, casts, bacteria, triple phosphate
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes
- full histopathology was performed with tissues from control, 3000 and 10000 ppm dose groups including: mammary gland, mesentheric and submandibular lymph nodes, pancreas, stomach, intestine at 6 levels, spleen, liver, adrenals, kidneys, ovaries, testes, uterus, prostate, seminal vesicles, urinary bladder, thyroids with oesophagus and trachea, heart, lungs, thymus, eyes and lachrymal glands, salivary gland, brain, spinal cord, pituitary, tongue, sciatic nerves, muscle, knee joint and femur - Other examinations:
- ORGAN WEIGHT:
- The following organs, removed from animals that were killed at study termination (13 weeks) were weighed: brain, heart, liver, spleen, kidneys, testes, ovaries, - Statistics:
- Body and organ weights were analysed by covariance analysis using initial bodyweight as the covariate. Reported means were adjusted for initial bodyweight if a significant covariance relationship existed; where no significant covariance relationship was found, unadjusted means were reported. Organ weights were further examined by covariance analysis using the terminal bodyweight as the covariate. The organ weight means are reported as adjusted for terminal bodyweight if a significant covariance relationship existed; the absence of a significant covariance relationship is indicated where appropriate. Food intakes, clinical chemical and haematological variates were examined using a two-way analysis of variance. The significance of any difference between treated and control group means was tested using the Williams “t” test. On occasions where a monotonic dose response was not seen Dunett´s test was used.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- significantly decreased body weight in the 10000 ppm group (both sexes) and in the 3000 ppm group (females) (non-adverse)
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- significantly decreased mean food intake in the 10000 ppm group (both sexes) (non-adverse)
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- significantly increased WBC, absolute lymphocytes in the 3000 ppm and 10000 ppm group (males); significantly increased WBC, lymphocytes and significantly decreased mean cell volume, mean cell haemoglobin in the 10000 ppm group (females) (non-adverse)
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- significantly increased urea, calcium, potassium in the 10000 ppm group (males); significantly increased urea, chloride, calcium, cholesterol in the 10000 ppm group (females) (non-adverse)
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- significantly increased liver weights in the 1000 ppm (females), 3000 and 10000 ppm (males) group; significantly increased spleen weight in the 10000 ppm group (males); significantly increased kidney weights in the 1000 ppm group (females) (non-adverse)
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY
There were no treatment-related clinical signs in either sex throughout the study. No mortality occurred during the entire study period.
BODY WEIGHT AND WEIGHT GAIN
The mean body weights of males fed 10000 ppm and of females fed 10000 ppm and 3000 ppm of the test material were significantly lower throughout the study period when compared to the control group. It seems clear that this was directly attributable to the reduced intake of an unpalatable diet. Further evidence of this was the increased food spillage in the same treatment groups (refer to table 1).
FOOD CONSUMPTION AND COMPOUND INTAKE
The food intakes of males and females fed 10000 ppmof the test material were significantly lower throughout the study when compared to the control group. Males and females in the 3000 ppm treatment group had lower food intakes, but these were only statistically significantly lower than control values at week 3 (males) and at weeks 5, 8, 10, 12 and 13 (females). The food spillage by both males and females fed 10000 ppm of the test material was higher than in other treatment groups (refer to table 2).
HAEMATOLOGY
In one or both sexes fed 10000 ppm of the test material, values of total leukocytes and absolute lymphocytes were significantly increased and values of absolute neutrophils, percentage neutrophils, mean cell volume, mean cell haemoglobin, and prothrombin time were significantly decreased when compared with controls. In the 3000 ppm group only the male values of total leukocytes, absolute lymphocytes and prothrombin time differed significantly from those of male controls (refer to table 3).
CLINICAL CHEMISTRY
In rats fed 10000 ppm of the test material, plasma concentrations of urea, potassium, chloride, calcium and cholesterol and the plasma activity of alkaline phosphatase were significantly increased in one or both sexes, when compared with the control group. At lower dietary concentrations, the only difference from control was the significantly elevated plasma concentration of urea in 1000 ppm and 3000 ppm females (refer to table 6).
ORGAN WEIGHTS
When compared to control, heart and kidney weights of both sexes, brain weights of males and spleen weights of females all had significantly lower mean values in the 10000 ppm group when unadjusted or adjusted for initial body weight but not after adjustment for terminal body weight. Liver weights of males in the 3000 ppm and 10000 ppm groups were significantly increased (when unadjusted and after adjustment for terminal body weight). Liver weights of females in the 1000 ppm and higher treatment groups showed a significant increase after adjustment for terminal body weight; adjustment for initial body weight showed a significant difference only at the 1000 ppm level. Adjustment for terminal body weight showed a significant increase in the spleen weight of males in the 10000 ppm group when compared with the controls. Females in the 1000 ppm group showed significantly increased kidney weights when adjusted for initial body weight and when adjusted for terminal body weight (refer to tables 5 and 6).
GROSS PATHOLOGY
No treatment-related macroscopic abnormalities were identified at necropsy.
HISTOPATHOLOGY
Histological examination revealed no specific effects attributable to exposure to the test material; neither the incidence nor the severity of spontaneous background lesions was significantly influenced by treatment.
Effect levels
- Dose descriptor:
- NOAEL
- Remarks:
- systemic
- Effect level:
- >= 500 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
Target system / organ toxicity
- Critical effects observed:
- no
Any other information on results incl. tables
Table 1: Mean body weights for rats for 13 weeks
Dietary concentration [ppm] |
Number of animals |
Mean body weight [g] at week |
|||||||||||||
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
||
Males 0 300 1000 3000 10000 |
24 12 12 12 12 |
|
+ a |
+ |
+ |
+ a |
+ |
+ |
+ a |
+ |
+ |
+ |
+ |
+ |
+ |
143 |
203 |
244 |
294 |
337 |
361 |
384 |
403 |
421 |
433 |
442 |
448 |
460 |
468 |
||
143 |
202 |
243 |
292 |
332 |
358 |
379 |
397 |
413 |
427 |
440 |
449 |
462 |
466 |
||
142 |
204 |
246 |
295 |
336 |
361 |
380 |
402 |
416 |
432 |
442 |
453 |
467 |
471 |
||
141 |
201 |
242 |
289 |
333 |
356 |
377 |
399 |
416 |
430 |
440 |
451 |
459 |
466 |
||
138 |
178** |
215** |
258** |
292** |
316** |
331** |
350** |
364** |
375** |
386** |
388** |
398** |
409 |
||
SD of a single observation |
|
9.4 |
4.7 |
6.3 |
9.4 |
11.6 |
12.8 |
14.3 |
14.4 |
16.1 |
17.6 |
18.6 |
19.7 |
21.6 |
22.2 |
|
|||||||||||||||
Females 0 300 1000 3000 10000 |
24 12 12 12 12 |
|
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
130 |
161 |
183 |
207 |
224 |
239 |
247 |
259 |
270 |
276 |
283 |
285 |
291 |
294 |
||
131 |
162 |
183 |
205 |
223 |
235 |
244 |
256 |
266 |
274 |
281 |
286 |
291 |
293 |
||
132 |
162 |
185 |
207 |
226 |
241 |
151 |
262 |
270 |
279 |
286 |
287 |
294 |
296 |
||
132 |
158* |
178* |
199* |
214** |
226** |
233** |
246** |
253** |
262** |
267** |
269** |
274** |
276** |
||
130 |
141** |
160** |
180** |
193** |
201** |
211** |
223** |
226** |
234** |
238** |
237** |
241** |
242** |
||
SD of a single observation |
|
7.6 |
3.4 |
5.8 |
8.6 |
10.4 |
11.4 |
12.5 |
12.9 |
12.7 |
13.0 |
13.0 |
13.2 |
14.3 |
14.3 |
+: adjusted for initial body weight
*: p ≤0.05
**: p ≤0.01
a: body weight measured 1 day late
SD: standard deviation
Table 2: Mean food intake for rats for 13 weeks
Dietary concentration [ppm] |
Number of animals |
Mean food intake [g] at week |
||||||||||||
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
||
Males 0 300 1000 3000 10000 |
24 12 12 12 12 |
a |
b |
|
a |
b |
|
a |
b |
|
|
|
|
|
182 |
152 |
187 |
217 |
160 |
178 |
213 |
162 |
181 |
179 |
171 |
176 |
174 |
||
183 |
150 |
185 |
216 |
163 |
170 |
206 |
157 |
179 |
181 |
177 |
181 |
171 |
||
181 |
150 |
186 |
217 |
161 |
171 |
207 |
154 |
178 |
182 |
180 |
183 |
171 |
||
180 |
150 |
178* |
216 |
155 |
172 |
211 |
158 |
179 |
179 |
176 |
173 |
167 |
||
146** |
130** |
161** |
192** |
140** |
148** |
180** |
133** |
150** |
162** |
144** |
154** |
151** |
||
SD of a single observation |
|
9.2 |
8.1 |
10.3 |
10.0 |
10.3 |
14.5 |
11.1 |
10.2 |
9.7 |
13.3 |
10.6 |
13.9 |
12.6 |
|
|
|||||||||||||
Females 0 300 1000 3000 10000 |
24 12 12 12 12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
133 |
135 |
142 |
145 |
138 |
138 |
150 |
150 |
145 |
150 |
138 |
146 |
139 |
||
136 |
136 |
139 |
141 |
138 |
126 |
145 |
144 |
144 |
147 |
141 |
139 |
134 |
||
134 |
137 |
139 |
145 |
145 |
141 |
152 |
144 |
150 |
149 |
145 |
148 |
140 |
||
127 |
130 |
138 |
137 |
129* |
125 |
145 |
137** |
136 |
141** |
136 |
136* |
129** |
||
97** |
121** |
125** |
124** |
117** |
114** |
135** |
118** |
126** |
120** |
115** |
122** |
108** |
||
SD of a single observation |
|
8.5 |
10.2 |
12.5 |
13.3 |
10.2 |
17.9 |
13.9 |
9.7 |
15.4 |
8.7 |
10.2 |
10.6 |
9.9 |
+: adjusted for initial body weight
*: p≤0.05
**: p≤0.01
a: food intake measured over an 8 day period
b: food intake measured over a 6 day period
SD: standard deviation
Table 3: Mean haematological values for rats for 13 weeks
Dietary concentration [ppm] |
Number of animals |
Haematology parameters |
||||||||||
WBC x10^3/cmm |
RBC x10^6/cmm |
Hb g/100 mL |
Hct % |
Mean cell volume µ3 |
Mean cell haemoglobin pg |
Platelets |
Mean cell haemoglobin concentration g/100 mL |
P.T. sec |
KCCT sec |
|||
Males 0 300 1000 3000 10000 |
24 12 11 11 12 |
|
|
|
|
|
|
|
|
|
|
|
3.91 |
7.93 |
15.3 |
42.0 |
54 |
19.5 |
543.6 |
36.5 |
15.4 |
30.0 |
|||
4.18 |
7.90 |
15.3 |
42.0 |
54 |
19.5 |
560.8 |
36.5 |
15.5 |
31.7 |
|||
3.99 |
7.94 |
15.3 |
42.0 |
54 |
19.4 |
544.1 A |
36.6 |
15.2 A |
28.7 A |
|||
4.50* |
8.12 |
15.4 |
42.3 |
53 |
19.1 |
558.8 |
36.5 |
14.4* |
27.0 |
|||
4.64** |
7.96 |
15.4 |
42.7 |
54 |
19.5 |
571.4 |
36.2 |
14.4* |
28.2 |
|||
SD of a single observation |
|
0.71 |
0.287 |
0.43 |
1.27 |
1.2 |
0.45 |
74.51 |
0.48 |
1.35 |
5.47 |
|
|
|
|||||||||||
Females 0 300 1000 3000 10000 |
22 12 12 11 12 |
|
|
|
|
|
|
|
|
|
|
|
2.63 |
7.41 |
15.1 |
41.4 |
56 |
20.5 |
531.0 |
36.5 |
12.8 |
21.9 |
|||
2.66 |
7.49 |
15.2 |
41.3 |
55 |
20.4 |
516.7 |
36.9 |
12.6 |
21.9 |
|||
2.83 |
7.44 |
15.1 |
41.6 |
56 |
20.5 |
522.1 |
36.5 |
13.0 |
22.3 |
|||
2.70 |
7.61 |
15.4 |
42.2 |
55 |
20.4 |
546.9 |
36.6 |
12.7 |
21.5 |
|||
3.02* |
7.53 |
14.9 |
41.0 |
54** |
19.9** |
586.7 |
36.4 |
13.0 |
21.5 |
|||
SD of a single observation |
|
0.504 |
0.324 |
0.55 |
1.48 |
1.1 |
0.43 |
85.02 |
0.42 |
0.60 |
2.07 |
*: p≤0.05
**: p≤0.01
SD: standard deviation
A: based on 12 observations
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.